Safdar A. Crit Care Med. 2010 Jan;38(1):293-4. doi: 10.1097/CCM.0b013e3181bfeabc. Comment on Characteristics and outcomes of patients with cancer requiring admission to intensive care units: a prospective multicenter study. [Crit Care Med. 2010]
Safdar A. Curr Fungal Infect Rep. 2010 Mar;4(1):1-7. Understanding fungal pathogenesis and host-pathogen immune interaction at various stages of infection is critical to examine strategies for bolstering antifungal immune defenses. Recombinant myeloid growth factors, especially granulocyte-macrophage colony-stimulating factor and the protagonist T helper (Th) 1 cytokine, interferon-γ, are most frequently used in patients with refractory invasive aspergillosis. These cytokines are […]
Safdar A. Intensive Care Med. 2010 Jul;36(7):1110-1. doi: 10.1007/s00134-010-1883-8. Epub 2010 Apr 16. Comment on Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. [Intensive Care Med. 2010] Int
Safdar A. N Engl J Med. 2010 Apr 15;362(15):1444-5; author reply 1445-6. Comment on Treatment with monoclonal antibodies against Clostridium difficile toxins. [N Engl J Med. 2010]
Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, Mattiuzzi GN, Chandrasekar PH, Kontoyiannis DP, Rolston KV, Walsh TJ, Champlin RE, Raad II. Medicine (Baltimore). 2010 Jul;89(4):236-44. Lipid preparations of amphotericin B, commonly used to treat fungal infections, have been demonstrated to have reduced nephrotoxicity compared to conventional amphotericin B. However, to our knowledge, a […]
Decker WK, Safdar A. Expert Rev Vaccines. 2010 Jul;9(7):721-30. Prophylactic vaccination of cancer patients and recipients of hematopoietic stem cell transplant is generally a simple, efficient and cost-effective manner by which to prevent unnecessary infection and enhance overall clinical outcomes. However, some neoplastic conditions, particularly B-cell malignancies, impart a degree of immunosuppression that complicates traditional prophylactic approaches. Here, […]
Decker WK, Safdar A. Cytokine Growth Factor Rev. 2011 Aug;22(4):177-87. Vaccination, the revolutionary prophylactic immunotherapy developed in the eighteenth century, has become the most successful and cost-effective of medical remedies available to modern society. Due to the remarkable accomplishments of the past century, the number of diseases and pathogens for which a traditional vaccine approach might reasonably […]
Safdar A, Armstrong D. Clin Infect Dis. 2011 Oct;53(8):798-806. Infections are common in patients with hematologic neoplasms and following allogeneic hematopoietic transplantation. Neutropenia and defects in adaptiveB-cell-mediated immunity and/or lack of splenic function predispose patients to a host of diverse and often serious infections. It is important to recognize that patients who undergo treatment for hematologic neoplasms […]
Safdar A. Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):1883-7. Patients with pulmonary nontuberculous mycobacteriosis (pNTM) may have suboptimum response to conventional antimicrobial therapy. Aerosolized amikacin (aeAmk) was given to nine patients who had failed standard combination oral antimycobacterial drugs. A favorable toxicity profile, even in patients given aeAmk for an extended duration, median 75 ± 85 (range, […]
Rodriguez GH, Ahmed SI, Al-akhrass F, Rallapalli V, Safdar A. Leuk Lymphoma. 2012 Aug;53(8):1530-5. Dasatinib has transformed the treatment of chronic myelogenous leukemia, resulting in durable remissions and prolonged survival. The spectrum of infectious complications during and after dasatinib therapy is not known. Retrospective analysis of records among 69 patients treated with dasatinib showed that 35 (51%) developed 57 […]